P Pavlakou1, E Liberopoulos2, E Dounousi3, M Elisaf2. 1. Department of Nephrology, Medical School, University of Ioannina, 45 110, Ioannina, Greece. 2. Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece. 3. Department of Nephrology, Medical School, University of Ioannina, 45 110, Ioannina, Greece. evangeldou@gmail.com.
Abstract
PURPOSE: Chronic kidney disease (CKD) is accompanied by a number of secondary metabolic dysregulations, such as lipid abnormalities, presenting with unique characteristics. Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors have been introduced as the new era in the management of dyslipidemia with promising results in groups with refractory lipid abnormalities. Increasing number of studies investigate the possible association of PCSK9 levels with kidney function, especially with nephrotic range proteinuria, as well as its role as a prognostic cardiovascular risk marker in CKD. In this review, we discuss the existing evidence for PCSK9 levels in patient groups with nephrotic syndrome, non-dialysis CKD, end-stage renal disease and kidney transplantation. METHODS: Online research was conducted in MEDLINE database to identify articles investigating PCSK9 in all different aspects of CKD. References from relevant studies were screened for supplementary articles. RESULTS: Four cross-sectional studies, one secondary analysis, one publication from two independent cohort studies and one multicentre prospective cohort study assessed PCSK9 plasma levels in different subgroups of CKD patients. PCSK9 levels increase in nephrotic syndrome and have a positive correlation with proteinuria. In CKD patients, no correlation was found between PCSK9 levels and estimated GFR. Peritoneal dialysis patients have higher PCSK9 levels compared with hemodialysis and renal transplant patients as well as general population. CONCLUSION: Accumulative evidence focuses on the possible association of PCSK9 levels with kidney function. No data are available for the administration of PCSK9 inhibitors in CKD patients. Further research will optimize knowledge on the role of PCSK9 levels and PCSK9 inhibitors in CKD.
PURPOSE:Chronic kidney disease (CKD) is accompanied by a number of secondary metabolic dysregulations, such as lipid abnormalities, presenting with unique characteristics. Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors have been introduced as the new era in the management of dyslipidemia with promising results in groups with refractory lipid abnormalities. Increasing number of studies investigate the possible association of PCSK9 levels with kidney function, especially with nephrotic range proteinuria, as well as its role as a prognostic cardiovascular risk marker in CKD. In this review, we discuss the existing evidence for PCSK9 levels in patient groups with nephrotic syndrome, non-dialysis CKD, end-stage renal disease and kidney transplantation. METHODS: Online research was conducted in MEDLINE database to identify articles investigating PCSK9 in all different aspects of CKD. References from relevant studies were screened for supplementary articles. RESULTS: Four cross-sectional studies, one secondary analysis, one publication from two independent cohort studies and one multicentre prospective cohort study assessed PCSK9 plasma levels in different subgroups of CKDpatients. PCSK9 levels increase in nephrotic syndrome and have a positive correlation with proteinuria. In CKDpatients, no correlation was found between PCSK9 levels and estimated GFR. Peritoneal dialysis patients have higher PCSK9 levels compared with hemodialysis and renal transplant patients as well as general population. CONCLUSION: Accumulative evidence focuses on the possible association of PCSK9 levels with kidney function. No data are available for the administration of PCSK9 inhibitors in CKDpatients. Further research will optimize knowledge on the role of PCSK9 levels and PCSK9 inhibitors in CKD.
Authors: Mary E Haas; Amy E Levenson; Xiaowei Sun; Wan-Hui Liao; Joseph M Rutkowski; Sarah D de Ferranti; Valerie A Schumacher; Philipp E Scherer; David J Salant; Sudha B Biddinger Journal: Circulation Date: 2016-07-05 Impact factor: 29.690
Authors: Gérald Luc; Jean-Marie Bard; Dominique Arveiler; Jean Ferrieres; Alun Evans; Philippe Amouyel; Jean-Charles Fruchart; Pierre Ducimetiere Journal: Atherosclerosis Date: 2002-08 Impact factor: 5.162
Authors: Hallvard Holdaas; Bengt Fellström; Alan G Jardine; Ingar Holme; Gudrun Nyberg; Per Fauchald; Carola Grönhagen-Riska; Søren Madsen; Hans-Hellmut Neumayer; Edward Cole; Bart Maes; Patrice Ambühl; Anders G Olsson; Anders Hartmann; Dag O Solbu; Terje R Pedersen Journal: Lancet Date: 2003-06-14 Impact factor: 79.321
Authors: Suetonia C Palmer; Sankar D Navaneethan; Jonathan C Craig; David W Johnson; Vlado Perkovic; Jorgen Hegbrant; Giovanni F M Strippoli Journal: Cochrane Database Syst Rev Date: 2014-05-31
Authors: Harold E Bays; Pam R Taub; Elizabeth Epstein; Erin D Michos; Richard A Ferraro; Alison L Bailey; Heval M Kelli; Keith C Ferdinand; Melvin R Echols; Howard Weintraub; John Bostrom; Heather M Johnson; Kara K Hoppe; Michael D Shapiro; Charles A German; Salim S Virani; Aliza Hussain; Christie M Ballantyne; Ali M Agha; Peter P Toth Journal: Am J Prev Cardiol Date: 2021-01-23